Apyx Medical Corporation
HealthcareNASDAQ:APYX · NASDAQ Global Select
+$0.04 today
Vol 0.16M · Avg 0.18M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-77.1%
avg -39.7%
ROIC
-11.6%
avg -24.6%
ROA
-16.8%
avg -14.6%
Analysis
ROIC is currently the strongest return metric at -11.6% versus its period average of -24.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Charles D. Goodwin | President, Chief Executive Officer & Director | $951,870.00 | — | 59 | $193,000.00 | 0.46% |
Matthew C. Hill | Chief Financial Officer, Treasurer & Secretary | $678,604.00 | — | 57 | $100,000.00 | 0.24% |
Moshe Citronowicz | Senior Vice President | $451,657.00 | — | 73 | $0.00 | <0.01% |
Shawn D. Roman | Chief Operating Officer | $426,072.00 | — | 54 | $12,000.00 | 0.03% |
Dolores Catania | Chief of Confidence | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +2.2% | +7.6% (13yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +2.2% over three years. Forward estimates point to Revenue at +7.6% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Pro-Dex, Inc.
NASDAQ:PDEX
$198.59M
Quipt Home Medical Corp.
QIPT
$162.30M
Lucid Diagnostics Inc.
NASDAQ:LUCD
$98.28M
AVITA Medical, Inc.
NASDAQ:RCEL
$97.14M
Rapid Micro Biosystems, Inc.
NASDAQ:RPID
$79.77M
Sera Prognostics, Inc.
NASDAQ:SERA
$71.42M
Vivani Medical, Inc.
NASDAQ:VANI
$64.99M
Xtant Medical Holdings, Inc.
AMEX:XTNT
$61.72M
InspireMD, Inc.
NSPR
$34.19M
Atossa Therapeutics, Inc.
ATOS
$21.18M
Who manages APYX?
Apyx Medical Corporation (APYX) lists 5 active executives. The top listed executive is Shawn D. Roman, Chief Operating Officer.
Are APYX insiders buying or selling?
Recent insider activity shows net buying of $19.95M.
Explore More
Continue the stock analysis
Jump to another research area for this company.